Ascending-Dose Study of Noribogaine in Healthy Volunteers: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability

Glue, Paul, Lockhart, Michelle, Lam, Fred, Hung, Noelyn, Hung, Cheung-Tak, Friedhoff, Lawrence · 2015 · Journal of Clinical Pharmacology

AI-extracted · unverified · confirm at source

First-in-human noribogaine Phase I: 3-60mg doses safe, well-tolerated. T½=28-49h, high Vd=1417-3086L, dose-linear PK. No mu-opioid agonist effects. Establishes human safety profile.

Dosing: 3–60 mg oral noribogaine (human) (oral)

Sample size: 36

Safety data present: QTC